Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Down 5.33%
As of Friday, October 23, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. NAMS
$20.06
-0.70
-3.37%
October 30, 2026 4:00:00 PM
EST
Volume: 1,140,394
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Commentary & Analysis
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 5.19%
As of Wednesday, September 30, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 5.19%, which has investors questioning if this is right time to sell.Jenna Brashear
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Up 5.15%
As of Thursday, September 17, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by 5.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why NewAmsterdam Pharma Company N.V.’s (NAMS) Stock Is Down 6.24%
As of Wednesday, September 09, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is NewAmsterdam Pharma Company N.V. (NAMS) Overvalued?
We dive into why NewAmsterdam Pharma Company N.V. (NAMS) could be considered overvalued on 2026-07-31, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,397.9 | $226.9 | 57% |
|
| Shares Out (Mil) | 123.4 | 53.4 | 66% |
|
| Institutional Ownership | 98.8% | 92.9% | 82% |
|
| Float (Mil) | 81.5 | 40.7 | 57% |
|
| Beta | 0.11 | 0.95 | 9% |
|
| Avg Daily Volume (000s) | 1,422 | 469 | 76% |
|
| Price Change (52-week) |
(44.0%) | 46.6% | 23% |
|
| Growth | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (96.3%) | (10.1%) | 2% |
|
| EPS (5yr) | (4.1%) | 15.8% | 26 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.3%) | (15.7%) | 17% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 12 | na | |
| Current EPS | ($0.486) | ($1.852) | na | |
| Month Ago EPS | ($0.485) | ($1.844) | na | |
| # Rev Up | 0 | 2 | na | |
| # Rev Down | 1 | 1 | na | |
| Three Months Ago EPS | ($0.474) | ($1.788) | na | |
| Year/Year Chg | (6.5%) | 7.6% | na | |
| Financials | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($260) | ($44) | 5% |
|
| EPS (TTM) | ($2.144) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($138) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $2,547 | $174 | 52% |
|
| Valuation | NAMS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.74 | 2.17 | 74% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NAMS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 65.6% | 96% |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (34.2%) | (47.1%) | 15% |
|
| ROE | (36.8%) | (53.0%) | 18% |
|
| Liabilities to Assets | 10.4% | 29.6% | 6% |
|
| F-Score | 3 | 2 | 18% |
|
NewAmsterdam Pharma Company N.V. did not pass any screens on 10/30/2026.
